```
FILE 'HOME' ENTERED AT 17:55:14 ON 08 DEC 2001

=> file uspatfull

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.15       0.15

FILE 'USPATFULL' ENTERED AT 17:55:31 ON 08 DEC 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 Dec 2001 (20011206/PD)
FILE LAST UPDATED: 6 Dec 2001 (20011206/ED)
HIGHEST GRANTED PATENT NUMBER: US6249914
HIGHEST APPLICATION PUBLICATION NUMBER: US2001049836
CA INDEXING IS CURRENT THROUGH 6 Dec 2001 (20011206/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 Dec 2001 (20011206/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2001
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2001

>>> Page images are available for patents from 1/1/1998.  Patents   <<<
>>> and applications are typically loaded on the day of publication.<<<
>>> Page images are available for display by the following day.     <<<
>>> Image data for the /FA field are available the following update.<<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<
>>> is included in file records.  A thesaurus is available for the  <<<
>>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL   <<<
>>> fields.  This thesaurus includes catchword terms from the       <<<
>>> USPTO/MOC subject headings and subheadings.  Thesauri are also  <<<
>>> available for the WIPO International Patent Classification      <<<
>>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4,     <<<
>>> /IC5, and /IC (/IC6) fields, respectively.  The thesauri in     <<<
>>> the /IC5 and /IC fields include the corresponding catchword     <<<
>>> terms from the IPC subject headings and subheadings.            <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s (anti-sense)

        218619 ANTI
        334268 SENSE
L1        6895 (ANTI-SENSE)
                 (ANTI(W)SENSE)

=> s (hcv or hepatitis c virus)

          1021 HCV
         12595 HEPATITIS
       1624362 C
         36886 VIRUS
           895 HEPATITIS C VIRUS
                 (HEPATITIS(W)C(W)VIRUS)
L2        1288 (HCV OR HEPATITIS C VIRUS)

=> s l1 and l2
```

```
L3          215 L1 AND L2

=> s (sabin 2)

            304 SABIN
        2961080 2
L4            9 (SABIN 2)
                (SABIN(W)2)

=> s l2 and l4

L5            0 L2 AND L4

=> s l2 and l4

L6            0 L2 AND L4

=> s sabin

L7          304 SABIN

=> s l7 and l3

L8            8 L7 AND L3

=> d l8 1-8 ab bib


L8   ANSWER 1 OF 8  USPATFULL
AB     The present invention provides methods of treating hepatitis C
       infections comprising the step of administering a vector construct
which
       directs the expression of at least one immunogenic portion of a
       hepatitis C antigen, such that an immune response is generated. Also
       provided are vector constructs which direct the expression of at least
       one portion of a hepatitis C antigen, as well as recombinant viruses
       which carry such vector constructs.
AN     2001:167936  USPATFULL
TI     Hepatitis therapeutics
IN     Jolly, Douglas J., Leucadia, CA, United States
       Chang, Stephen M. W., Poway, CA, United States
       Lee, William T. L., Carlsbad, CA, United States
       Townsend, Kay, Encinitas, CA, United States
       O'Dea, Joanne, La Jolla, CA, United States
PA     Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI     US 6297048          B1   20011002
AI     US 1995-483511           19950607 (8)
RLI    Continuation-in-part of Ser. No. US 1995-374414, filed on 19 Jan 1995,
       now abandoned Continuation-in-part of Ser. No. US 1994-286829, filed on
       5 Aug 1994, now abandoned Continuation-in-part of Ser. No. US
       1993-102132, filed on 4 Aug 1993, now abandoned Continuation-in-part of
       Ser. No. US 1993-32385, filed on 17 Mar 1993, now abandoned
       Continuation-in-part of Ser. No. US 1992-830417, filed on 4 Feb 1992,
       now abandoned
DT     Utility
FS     GRANTED
EXNAM  Primary Examiner: Schwartzman, Robert A.
LREP   Blackburn, Robert P., McMasters, David, Dollard, Anne S.
CLMN   Number of Claims: 7
ECL    Exemplary Claim: 6
DRWN   21 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 3732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8   ANSWER 2 OF 8  USPATFULL
```

AB The invention provides fusion proteins comprising an N-terminal region derived from an interferon-tau (IFN-.tau.) polypeptide and a C-terminal region derived from another type I interferon polypeptide, such as IFN-.alpha. or IFN-.beta.. The fusion proteins exhibit reduced cytotoxicity as compared to the corresponding unmodified type I interferons.
AN 2001:8162 USPATFULL
TI Hybrid interferon .tau./type I interferon polypeptides
IN Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
PA University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 6174996 B1 20010116
AI US 1998-45467 19980320 (9)
RLI Continuation of Ser. No. US 1995-455021, filed on 31 May 1995, now patented, Pat. No. US 5958402 Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363 Continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Petithory, Joanne R., Mohr, Judy M.Iota Pi Law Group
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 8 USPATFULL
AB The invention provides antitumor therapeutic methods employing bovine or
ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..
AN 1999:116974 USPATFULL
TI Antitumor therapy using ovine or bovine interferon-tau
IN Bazer, Fuller Warren, College Station, TX, United States
Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Ott, Troy Lee, Bryan, TX, United States
Van Heeke, Gino, Witterswil, Switzerland
PA University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 5958402 19990928
AI US 1995-455021 19950531 (8)
RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363 which is a continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned , said Ser. No. US 139891 which is a continuation-in-part of Ser. No. US 1992-969890, filed
on 30 Oct 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Sholtz, Charles K., Petithory, Joanne R.Dehlinger & Associates
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 8 USPATFULL
AB The invention provides antiviral therapeutic methods employing bovine or
ovine interferon-tau (IFN-.tau.) proteins and polypeptides. The IFN-.tau. proteins exhibit the antiviral and antiproliferative properties characteristic of type I interferons. An advantage of the invention is that IFN-.tau. has essentially no cytotoxic effects on treated cells as does, for example, IFN-.alpha..
AN 1999:99371 USPATFULL
TI Antiviral therapy using ovine or bovine interferon-tau
IN Bazer, Fuller Warren, College Station, TX, United States
Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Ott, Troy Lee, Bryan, TX, United States
Heeke, Gino Van, Witterswil, Switzerland
PA University of Florida, Gainesville, FL, United States (U.S. corporation)
PI US 5942223 19990824
AI US 1995-455524 19950531 (8)
RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363 which is a continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned , said Ser. No. US 139891 which is a continuation-in-part of Ser. No. US 1992-969890, filed
on 30 Oct 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Scholtz, Charles K., Petithory, Joanne R.Dehlinger & Associates
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 25 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3847
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 8 USPATFULL
AB The present invention describes hybrid interferon fusion polypeptides formed of a first segment that contains the N-terminal amino acid sequence of an interferon-tau polypeptide, and a second segment that contains the C-terminal amino acid sequence of a non-tau interferon type
I polypeptide. The two segments are joined in the region of a mature interferon polypeptide between about residues 8 and 37. Also described are nucleic acid sequences encoding such interferon fusion polypeptides,
expression vectors containing such sequences, and therapeutic applications of the interferon fusion polypeptides. The therapeutic applications include antiviral and anticellular proliferation applications. One advantage of the interferon fusion polypeptides of the
present invention is that they do not have cytotoxic side-effects when used to treat cells.
AN 1999:96237 USPATFULL
TI Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
IN Johnson, Howard Marcellus, Gainesville, FL, United States
Pontzer, Carol Hanlon, Silver Spring, MD, United States
Subramaniam, Prem Shankar, Gainesville, FL, United States
PA University of Florida, Gainesville, FL, United States (U.S. corporation)

PI US 5939286 19990817
AI US 1996-631328 19960412 (8)
RLI Continuation-in-part of Ser. No. US 1995-438753, filed on 10 May 1995, now patented, Pat. No. US 5705363
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Petithory, Joanne R., Sholtz, Charles K., Dehlinger, Peter J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 27 Drawing Page(s)
LN.CNT 4631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 8 USPATFULL
AB The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..
AN 1998:39242 USPATFULL
TI Human interferon .tau. proteins and methods of use
IN Imakawa, Kazuhiko, Derby, KS, United States
PA The Women's Research Institute, Wichita, KS, United States (U.S. corporation)
PI US 5738845 19980414
AI US 1995-443883 19950531 (8)
RLI Continuation of Ser. No. US 1995-438753, filed on 10 May 1995 which is a continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned , said Ser. No. US 1993-139891, filed on 19 Oct 1993 which is a continuation-in-part of Ser. No. US 1992-969890, filed on 30 Oct 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Sholtz, Charles K., Fabian, Gary R., Dehlinger, Peter J.
CLMN Number of Claims: 18
ECL Exemplary Claim: 1,7,10
DRWN 25 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 8 USPATFULL
AB The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..

AN 1998:1650 USPATFULL
TI Recombinant production of human interferon .tau. polypeptides and nucleic acids
IN Imakawa, Kazuhiko, Derby, KS, United States
PA The Women's Research Institute, Wichita, KS, United States (U.S. corporation)
PI US 5705363 19980106
AI US 1995-438753 19950510 (8)
RLI Continuation-in-part of Ser. No. US 1993-139891, filed on 19 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-847741, filed on 9 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-318050, filed on 2 Mar 1989, now abandoned , said Ser. No. US -139891 which is a continuation-in-part of Ser. No. US 1992-969890, filed on 30 Oct 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Fitzgerald, David L.
LREP Sholtz, Charles K., Fabian, Gary R., Dehlinger, Peter J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 21 Drawing Page(s)
LN.CNT 3635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 8 USPATFULL
AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.
AN 97:117939 USPATFULL
TI Methods and compositions for inhibiting production of replication competent virus
IN Klump, Wolfgang M., Del Mar, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
PA Chiron Corporation, United States (U.S. corporation)
PI US 5698446 19971216
AI US 1994-305699 19940907 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Kruse, Norman J., Blackburn, Robert P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s (IRBS or internal ribosome binding site)

20 IRBS
699231 INTERNAL
7424 RIBOSOME
146168 BINDING
211359 SITE
26 INTERNAL RIBOSOME BINDING SITE
(INTERNAL(W)RIBOSOME(W)BINDING(W)SITE)
L9 45 (IRBS OR INTERNAL RIBOSOME BINDING SITE)

=> s l2 and l9

L10 6 L2 AND L9

=> s l10 and l1

L11 2 L10 AND L1

=> d l11 1-2 ab bib

L11 ANSWER 1 OF 2 USPATFULL
AB Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.
AN 1998:36597 USPATFULL
TI Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells
IN Chada, Sunil, 1542 Enchantment Ave., Vista, CA, United States 92083
Dubensky, Jr., Thomas W., 12729 via Felino, Del Mar, CA, United States 92014
PI US 5736388 19980407
AI US 1994-366522 19941230 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Chambers, Jasemine C.; Assistant Examiner: Priebe, Scott D.
LREP Kruse, Norman J., Blackburn, Robert P.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 2215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 2 USPATFULL
AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.
AN 97:117939 USPATFULL
TI Methods and compositions for inhibiting production of replication competent virus
IN Klump, Wolfgang M., Del Mar, CA, United States
Jolly, Douglas J., Leucadia, CA, United States
PA Chiron Corporation, United States (U.S. corporation)
PI US 5698446 19971216
AI US 1994-305699 19940907 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Kruse, Norman J., Blackburn, Robert P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2090

~~CAS INDEXING IS AVAILABLE FOR THIS PATENT.~~

=> d l10 1-6 ab bib

L10 ANSWER 1 OF 6 USPATFULL
AB Peptides and RNA oligonucleotides and methods of use for the inhibition of translation of an mRNA, which is initiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, are disclosed. Peptides comprising the La autoantigen binding domain (LAP) are disclosed. LAP peptides alone or in combination with inhibitor RNA oligonucleotides (IRNA) may be used as antiviral agents to inhibit internal ribosome entry site (IRES) mediated viral replication.
AN 2001:158455 USPATFULL
TI Interference with viral IRES-mediated translation by a small yeast RNA reveals critical RNA-protein interactions
IN Das, Saumitra, Los Angeles, CA, United States
Dasgupta, Asim, Los Angeles, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6291637 B1 20010918
AI US 1999-316630 19990521 (9)
RLI Continuation-in-part of Ser. No. US 1997-817953, filed on 6 Oct 1997, now patented, Pat. No. US 5989904 Continuation-in-part of Ser. No. US 1994-321427, filed on 11 Oct 1994, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: McGarry, Sean
LREP Morrison & Foerster LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 20 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 2234
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 6 USPATFULL
AB Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.
AN 2000:4680 USPATFULL
TI Crossless retroviral vectors
IN Respess, James G., San Diego, CA, United States
DePolo, Nicholas J., Solana Beach, CA, United States
Chada, Sunil, Missouri City, TX, United States
Sauter, Sybille, Del Mar, CA, United States
Bodner, Mordechai, San Diego, CA, United States
Driver, David A., San Diego, CA, United States
PA Chiron Corporation, Emeryville, CA, United States (U.S. corporation)
PI US 6013517 20000111
AI US 1997-850961 19970505 (8)
RLI Continuation-in-part of Ser. No. US 1996-721327, filed on 26 Sep 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-643411, filed on 6 May 1996, now abandoned which is a

continuation-in-part of Ser. No. US 1995-437465, filed on 9 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-240030, filed on 9 May 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Guzo, David
LREP Blackburn, Robert P.
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 28 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 6 USPATFULL
AB A method to inhibit translation of an mRNA, which is intitiated at an internal ribosome entry site of the mRNA and requires binding of a protein factor to that site, is disclosed. The method comprises a step of providing, in an in vitro, or in vivo system that is capable of translating the mNRA, an inhibitory effective amount of a molecule that selectively binds to the protein factor, thereby preventing that factor from binding to the mNRA. The inhibitor molecule is an RNA oligonucleotide consisting of less than 35 nucleotides or a structural mimic of such an RNA oligonucleotide. Nucleotide sequences of such inhibitor RNA oligonucleotides include portions of the following sequences: the 60 nucleotide sequence of a yeast inhibitor RNA or of the
sequence complementary to that yeast inhibitor RNA; nucleotides 186-220 of poliovirus (stem-loop D); nucleotides 578-618 of poliovirus (stem-loop G); nucleotides 260-415 of poliovirus (stem-loop E); nucleotides 448-556 of poliovirus (stemp-loop F); and the sequence of the internal ribosome entry site of the immunoglobulin heavy chain binding protein (Bip).
AN 1999:151007 USPATFULL
TI Selective inhibition of internally initiated RNA translation
IN Das, Saumitra, Los Angeles, CA, United States
Dasgupta, Asim, Los Angeles, CA, United States
Coward, Peter, San Francisco, CA, United States
PA The Regents of the University of California, Los Angeles, CA, United States (U.S. corporation)
PI US 5989904 19991123
WO 9611211 19960418
AI US 1997-817953 19971006 (8)
WO 1995-US12615 19951011
19971006 PCT 371 date
19971006 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-321427, filed on 11 Oct 1994
DT Utility
FS Granted
EXNAM Primary Examiner: LeGuyader, John; Assistant Examiner: McGarry, Sean
LREP Morrison & Foerster, LLP
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN 31 Drawing Figure(s); 17 Drawing Page(s)
LN.CNT 2103
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 6 USPATFULL
AB Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic

transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.

AN 1998:36597 USPATFULL

TI Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells

IN Chada, Sunil, 1542 Enchantment Ave., Vista, CA, United States 92083
Dubensky, Jr., Thomas W., 12729 via Felino, Del Mar, CA, United States 92014

PI US 5736388 19980407

AI US 1994-366522 19941230 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Chambers, Jasemine C.; Assistant Examiner: Priebe, Scott D.

LREP Kruse, Norman J., Blackburn, Robert P.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 2 Drawing Page(s)

LN.CNT 2215

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 6 USPATFULL

AB The present invention provides methods and compositions for inhibiting the production of replication competent virus. The invention comprises nucleic acid cassettes encoding a non-biologically active inhibitory molecule which are incorporated into packaging cells and recombinant vector constructs. Upon recombination between various vector construct contained within the producer cell, a biologically active molecule is produced which kills the cell, thereby inhibiting production of replication competent virus.

AN 97:117939 USPATFULL

TI Methods and compositions for inhibiting production of replication competent virus

IN Klump, Wolfgang M., Del Mar, CA, United States
Jolly, Douglas J., Leucadia, CA, United States

PA Chiron Corporation, United States (U.S. corporation)

PI US 5698446 19971216

AI US 1994-305699 19940907 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Guzo, David

LREP Kruse, Norman J., Blackburn, Robert P.

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 23 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 2090

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 6 USPATFULL

AB A method for detecting multiple subpopulations of analytes of interest in a sample employing a complementary binding moiety to each of said analytes bound to a solid support, wherein each analyte and its complementary binding moiety comprise first and second members of a specific binding pair (msbp) respectively is provided. The method includes the steps of forming a mixture of known proportions of multiple subpopulations of said complementary binding moieties, wherein each subpopulation comprises a different complementary binding moieties, contacting the sample with the mixture so that specific binding pairs are formed on the solid supports, and relating the presence of analytes of interest in the sample to the formation of specific binding pairs associated with each unique proportion of said multiple subpopulations. The method can be performed with solid supports of a single average size and a single fluorochrome and without the need for using three detection

systems (fluorescence FS & SS). Also provided is a relatively low cost flow cytometer which can be used with the subject method.
AN 96:96966 USPATFULL
TI Method and composition for the simultaneous and discrete analysis of multiple analytes
IN Lehnen, Brian C., San Carlos, CA, United States
PA Trans-Med Biotech, Incorporated, S. South Francisco, CA, United States (U.S. corporation)
PI US 5567627 19961022
AI US 1993-149129 19931105 (8)
DCD 20120923
RLI Continuation of Ser. No. US 1991-731039, filed on 16 Jul 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Saunders, David; Assistant Examiner: Chin, Christopher L.
LREP Rowland, Bertram I.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	34.08	34.23

FILE 'BIOSIS' ENTERED AT 18:00:16 ON 08 DEC 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 5 December 2001 (20011205/ED)

The BIOSIS file has been reloaded. Enter HELP RLOAD and HELP REINDEXING for details.

=> s l10

```
         13535 HCV
         88313 HEPATITIS
        913018 C
        431224 VIRUS
         21258 HEPATITIS C VIRUS
                 (HEPATITIS(W)C(W)VIRUS)
            18 IRBS
        116555 INTERNAL
         12725 RIBOSOME
        518302 BINDING
        354954 SITE
             6 INTERNAL RIBOSOME BINDING SITE
                 (INTERNAL(W)RIBOSOME(W)BINDING(W)SITE)
L12          0 L2 AND L9
```